Homologous recombination deficiency positive advanced ovarian cancer – Life with Disease

Go back

Homologous recombination deficiency positive advanced ovarian cancer is a specific type of ovarian cancer where tumor cells cannot properly repair damaged DNA, making them more sensitive to certain treatments. Testing for this condition helps doctors determine the best treatment approach for each patient.

Understanding Your Prognosis

When you or a loved one receives a diagnosis of homologous recombination deficiency (HRD) positive advanced ovarian cancer, understanding what lies ahead can feel overwhelming. Prognosis refers to the likely course and outcome of the disease, and having HRD-positive status can actually provide important information about how your cancer may respond to treatment.[1]

Research has shown that patients with HRD-positive tumors tend to respond better to certain treatments compared to those without this characteristic. In studies examining Chinese patients with high-grade serous ovarian carcinoma, those with HRD-positive status showed significantly improved progression-free survival, with a median of 30.5 months compared to 16.8 months in HRD-negative patients. This means that on average, the time before the disease progressed was nearly twice as long for HRD-positive patients.[8]

It’s important to understand that approximately 50% of women with advanced ovarian cancer have tumors that test positive for HRD, which means this condition is relatively common among ovarian cancer patients. About half of these cases involve mutations in the BRCA1 or BRCA2 genes, but many others have HRD due to different genetic or cellular factors.[3][16]

The presence of HRD in your tumor tissue makes cancer cells more vulnerable to specific therapies, particularly PARP inhibitors—medications that block a protein called poly (ADP-ribose) polymerase, which cancer cells need for repair—and platinum-based chemotherapy drugs. Because your cancer cells already have difficulty repairing DNA breaks due to HRD, these treatments can be especially effective at stopping cancer growth.[12]

⚠️ Important
Every person’s cancer is unique, and statistics represent averages across many patients. Your individual outcome depends on multiple factors including your overall health, the specific characteristics of your tumor, how well you respond to treatment, and the stage at which your cancer was diagnosed. Always discuss your personal prognosis with your healthcare team, who can provide guidance based on your specific situation.

Natural Progression Without Treatment

Understanding how HRD-positive advanced ovarian cancer develops when left untreated can help you appreciate why timely intervention matters. Advanced ovarian cancer means the disease has already spread beyond the ovaries, typically to other parts of the abdomen or pelvis, and sometimes to more distant organs.[6]

In ovarian cancer with homologous recombination deficiency, the cells have lost their ability to repair double-strand breaks in DNA effectively. This happens because of mutations in genes responsible for the homologous recombination repair pathway—a complex system that normally fixes damaged DNA by using a second copy of the gene as a template. When this system fails, cells must rely on other, more error-prone repair methods. Over time, these faulty repairs lead to an accumulation of genetic mistakes, insertions, and deletions throughout the DNA, which allows cancer cells to grow and spread.[4]

Without treatment, cancer cells continue to multiply and invade surrounding tissues. The tumor can grow larger within the pelvis and abdomen, potentially blocking the intestines or affecting other organs. Cancer cells may also spread through the peritoneal fluid—the liquid that surrounds abdominal organs—allowing the disease to seed new tumor sites throughout the abdominal cavity.[6]

As the disease progresses, symptoms typically worsen. You might experience increasing abdominal swelling due to fluid buildup (called ascites), more severe abdominal pain, difficulty eating or feeling full quickly, changes in bowel habits, and increasing fatigue. The cancer may eventually interfere with normal organ function, affecting the kidneys, liver, or lungs if it spreads to these areas.[4]

Possible Complications

Even with treatment, HRD-positive advanced ovarian cancer can lead to various complications that affect different parts of your body. Understanding these potential issues helps you and your healthcare team watch for warning signs and address problems early.

One significant complication is bowel obstruction, which occurs when the tumor grows large enough to block the intestines or when scar tissue from surgery or disease progression narrows the digestive tract. This can cause severe cramping, vomiting, inability to pass gas or stool, and require emergency medical attention. In some cases, surgery or other interventions become necessary to relieve the blockage.[6]

Fluid accumulation in the abdomen, known as ascites, is another common complication. As cancer spreads throughout the abdominal cavity, it can irritate the lining and cause fluid to build up. This creates uncomfortable bloating, difficulty breathing when the fluid pushes against your diaphragm, and a feeling of fullness that makes eating difficult. Healthcare providers may need to drain this fluid periodically to improve comfort and quality of life.

Cancer cells can spread to the lungs, either directly or through the bloodstream, causing difficulty breathing, persistent cough, or chest pain. When fluid accumulates around the lungs (called pleural effusion), it can further compromise breathing and require drainage procedures.

Treatment itself can bring complications. Chemotherapy and targeted therapies may cause side effects including nausea, fatigue, changes in blood cell counts that increase infection risk, hair loss, and nerve damage. PARP inhibitors, commonly used for HRD-positive cancers, may cause anemia (low red blood cell count), fatigue, nausea, and in rare cases, more serious blood disorders or lung problems.[3][10]

Nutritional complications frequently develop as the disease progresses. Difficulty eating due to early fullness, nausea, or intestinal issues can lead to weight loss and malnutrition, which in turn affects your body’s ability to tolerate treatment and fight infection. Working with nutritionists who specialize in cancer care can help address these challenges.

Blood clots represent another serious risk for ovarian cancer patients. Cancer cells can make blood more prone to clotting, and decreased mobility during treatment increases this risk further. Blood clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism) require immediate medical attention and ongoing treatment with blood-thinning medications.

Impact on Daily Life

Living with HRD-positive advanced ovarian cancer affects virtually every aspect of daily life, from physical abilities to emotional wellbeing, relationships, work, and leisure activities. Understanding these impacts helps you plan for support and adapt your routines.

Physically, the disease and its treatment often cause profound fatigue that goes beyond normal tiredness. You might find that activities you once did easily—grocery shopping, cleaning the house, or even showering—now exhaust you. This fatigue doesn’t always improve with rest and can be one of the most challenging symptoms to manage. Planning your day around your energy levels, prioritizing essential activities, and asking for help with less critical tasks becomes necessary.

Treatment schedules can dominate your calendar. Chemotherapy sessions, doctor appointments, blood tests, and scans require significant time commitments. If you’re receiving combination therapy with a PARP inhibitor and bevacizumab for first-line maintenance treatment, you’ll need regular monitoring visits to check for side effects and assess how well the treatment is working. This can make maintaining regular work schedules or social commitments challenging.[10][11]

Emotionally, a cancer diagnosis brings anxiety, fear, and sometimes depression. Worrying about treatment outcomes, potential recurrence, and the future is normal. You might experience mood swings, difficulty concentrating, or changes in how you view yourself and your body. These emotional responses are as real and important as physical symptoms and deserve attention and care.

Work life often requires significant adjustments. Some patients can continue working during treatment, perhaps with reduced hours or modified duties. Others need to take extended medical leave. The unpredictability of symptoms and treatment side effects can make consistent attendance difficult. Having conversations with your employer about your needs, exploring flexible work arrangements, and understanding your legal protections regarding medical leave helps manage this aspect of life.

Relationships with family and friends may shift. Some people struggle to understand what you’re experiencing, while others may not know how to help or what to say. Communication becomes crucial—letting loved ones know what kind of support you need, whether that’s practical help with meals and transportation, someone to accompany you to appointments, or simply someone to listen when you need to talk.

Intimate relationships can be affected by physical symptoms, fatigue, body image changes, and emotional stress. Open, honest communication with your partner about these challenges helps maintain connection during difficult times. Some couples benefit from counseling to navigate these changes together.

Financial concerns add another layer of stress. Even with insurance, treatment costs can be substantial. You may face bills for medications, copays for numerous appointments, and costs for supportive care services. Some patients must reduce work hours or stop working entirely, affecting household income. Exploring financial assistance programs, talking with hospital financial counselors, and understanding your insurance coverage helps manage this burden.[3]

Hobbies and leisure activities that once brought joy may need modification. If you enjoyed gardening, you might need to work in shorter sessions or focus on less physically demanding tasks. If travel was a passion, you’ll need to plan around treatment schedules and ensure access to medical care wherever you go. Finding ways to adapt favorite activities rather than abandoning them entirely helps maintain quality of life and a sense of normalcy.

⚠️ Important
Many communities have support groups specifically for ovarian cancer patients where you can connect with others who understand what you’re experiencing. Social workers and patient navigators at cancer centers can help you access resources for practical, emotional, and financial support. You don’t have to manage everything alone—asking for and accepting help is a sign of strength, not weakness.

Support for Family Members

When someone you love has HRD-positive advanced ovarian cancer, you naturally want to help in any way possible. Understanding clinical trials and how to support your family member through testing and potential trial participation represents one meaningful way to be involved in their care.

Clinical trials are research studies that test new treatments or new ways of using existing treatments. For HRD-positive ovarian cancer, trials might investigate new PARP inhibitors, combinations of different drugs, or novel therapies targeting the specific weaknesses in cancer cells that can’t properly repair DNA. Participation in clinical trials can sometimes provide access to promising treatments before they become widely available.[12]

As a family member, you can help by first educating yourself about HRD and what it means for your loved one’s cancer. Understanding that HRD-positive status indicates the tumor has a specific vulnerability that certain treatments can exploit helps you grasp why testing was important and what treatment options might be available. Reading reliable sources of information together and attending medical appointments can help both of you stay informed.[13][14]

When it comes to clinical trials, start by having open conversations with your family member about their interest in participating. Some people feel hopeful about trying new treatments, while others prefer established therapies. Respect their wishes and values—your role is to support their decisions, not make decisions for them.

If your loved one is interested in clinical trials, you can help research available options. Many cancer centers have clinical trial coordinators who can explain studies currently enrolling patients. You can also search online databases, though it’s important to focus on trials specifically designed for HRD-positive advanced ovarian cancer. Write down questions to ask the research team about the trial’s purpose, what treatments are involved, potential risks and benefits, and what participation would require in terms of time and additional testing.[12]

Practical support matters enormously during the testing process and throughout treatment. Offer to drive to appointments, take notes during doctor visits, help organize medical records and test results, or manage the calendar of appointments. These seemingly small tasks can feel overwhelming when someone is dealing with cancer, and your help can reduce their stress significantly.

HRD testing itself requires tumor tissue samples, which might come from the original biopsy or surgery. Understanding that the test looks at the DNA profile of the tumor—checking for BRCA mutations and other signs of genomic instability—helps you explain to other family members why this test matters for treatment decisions. The results typically classify tumors as either HRD-positive or HRD-negative, which guides whether treatments like PARP inhibitors might be effective.[3][16]

Emotional support is equally crucial. Living with cancer brings fear, frustration, and sadness. Being present, listening without trying to fix everything, and acknowledging the difficulty of what your loved one is experiencing provides comfort. Sometimes the most helpful thing you can do is simply sit with them in their difficult emotions rather than trying to make them feel better immediately.

Coordinate with other family members and friends to create a support network. This might involve organizing meal deliveries, childcare help if your loved one has children, housekeeping assistance, or companionship during treatment sessions. Many communities use online platforms to coordinate help from multiple people, making it easier for everyone to contribute.

Take care of yourself too. Supporting someone with cancer is emotionally and physically demanding. You can’t pour from an empty cup—maintaining your own health, seeking support for yourself through counseling or support groups for caregivers, and taking breaks when needed helps you remain a strong source of support over the long term.

Help your loved one stay organized with medical information. Keep a binder or digital folder with test results, medication lists, insurance information, and contact details for the medical team. When discussing clinical trials or treatment options, having this information readily available makes conversations with healthcare providers more productive.

Finally, celebrate small victories and maintain hope while being realistic. Whether it’s completing a treatment cycle, receiving encouraging test results, or simply having a good day, acknowledging positive moments helps balance the difficulty of the cancer journey.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Olaparib (LYNPARZA) – A PARP inhibitor approved as maintenance treatment for HRD-positive advanced ovarian cancer following response to platinum-based chemotherapy, used in combination with bevacizumab or as monotherapy for patients with BRCA mutations
  • Niraparib – A PARP inhibitor indicated for HRD-positive advanced ovarian cancer that has shown benefit in clinical trials
  • Bevacizumab – An anti-cancer medicine used in combination with PARP inhibitors for first-line maintenance treatment in HRD-positive advanced ovarian cancer

Ongoing Clinical Trials on Homologous recombination deficiency positive advanced ovarian cancer

  • Study Comparing Niraparib and Platinum-Taxane Drug Combination for Patients with Advanced Ovarian Cancer

    Not recruiting

    1 1 1
    Spain

References

https://pmc.ncbi.nlm.nih.gov/articles/PMC9968181/

https://www.carislifesciences.com/physicians/physician-tests/whole-exome-sequencing/homologous-recombination-deficiency-hrd/

https://www.lynparza.com/ovarian-cancer/getting-tested.html

https://www.medicalnewstoday.com/articles/hrd-positive-ovarian-cancer

https://www.illumina.com/areas-of-interest/cancer/ngs-in-oncology/biomarkers/homologous-recombination-deficiency.html

https://www.azprecisionmed.hr/home/tumor-type/ovarian-cancer.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC12153926/

https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-023-01129-x

https://pmc.ncbi.nlm.nih.gov/articles/PMC9968181/

https://www.lynparzahcp.com/ovarian-cancer/testing/hrd-testing.html

https://www.merck.com/news/lynparza-olaparib-approved-in-china-as-first-line-maintenance-treatment-with-bevacizumab-for-homologous-recombination-deficient-hrd-positive-advanced-ovarian-cancer/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12153926/

https://www.futureofpersonalhealth.com/ovarian-cancer-awareness/hrd-the-test-everyone-with-advanced-ovarian-cancer-should-know-about/

https://www.testforhrd.com/

https://www.lynparza.com/ovarian-cancer/getting-tested.html

FAQ

What does HRD-positive mean for my ovarian cancer?

HRD-positive means your tumor cells cannot properly repair certain types of DNA damage due to defects in the homologous recombination repair pathway. This makes your cancer more sensitive to specific treatments like PARP inhibitors and platinum-based chemotherapy, potentially leading to better treatment responses and longer progression-free survival.

How is HRD testing different from BRCA genetic testing?

BRCA genetic testing looks for inherited mutations in specific genes (BRCA1 and BRCA2) using blood or saliva samples and can be done at any time. HRD tumor testing examines all the genes in your tumor’s DNA using tissue samples and looks for both BRCA mutations and other signs of genomic instability. HRD testing provides a more complete picture of your tumor’s repair deficiency and is done after cancer diagnosis.

When should I get tested for HRD?

You should talk to your doctor about HRD testing as soon as possible after being diagnosed with advanced ovarian cancer. Early testing helps determine whether treatments like PARP inhibitors in combination with bevacizumab may be appropriate first-line maintenance therapy options for you, and knowing your HRD status early can guide the entire course of your treatment planning.

Can I be HRD-positive even if I don’t have a BRCA mutation?

Yes, absolutely. Approximately half of HRD-positive cases do not involve BRCA mutations. HRD can result from mutations in other genes involved in DNA repair (such as RAD51, PALB2, CHEK2, and others) or from epigenetic factors that affect how genes work. This is why comprehensive HRD testing that looks beyond just BRCA mutations is important.

Will my family members be at risk if I have HRD-positive ovarian cancer?

The answer depends on whether your HRD is due to an inherited genetic mutation (germline) or one that developed during your lifetime (somatic). If HRD testing reveals an inherited BRCA mutation, your blood relatives may have inherited the same mutation and could benefit from genetic counseling and testing. However, if your HRD is due to somatic mutations or other factors that developed only in the tumor, these would not be passed to family members.

🎯 Key takeaways

  • About 50% of women with advanced ovarian cancer have HRD-positive tumors, making it a remarkably common characteristic that significantly influences treatment choices
  • HRD-positive patients showed nearly double the progression-free survival compared to HRD-negative patients in studies, highlighting why testing matters for prognosis
  • Even if you test negative for BRCA mutations, you could still be HRD-positive through other genetic pathways or epigenetic factors affecting DNA repair
  • HRD testing requires tumor tissue samples and looks at the overall DNA profile, not just individual genes, providing a comprehensive view of your cancer’s repair capabilities
  • The same DNA repair deficiency that allows cancer to develop becomes its weakness when treated with PARP inhibitors, creating a targeted treatment opportunity
  • Getting tested as early as possible after diagnosis helps determine if PARP inhibitors combined with bevacizumab may be suitable for first-line maintenance therapy
  • Family members can provide crucial support by helping research clinical trials, coordinating practical assistance, and accompanying patients to appointments while respecting their treatment decisions
  • Living with HRD-positive advanced ovarian cancer requires adjustments across all life areas—physical, emotional, work, and relationships—but many support resources exist to help navigate these challenges

Connected medications: